Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:02 PM ET 10-Q
Financial Results Grayscale Bitcoin Mini Trust ETF BTC

Grayscale Bitcoin Mini Trust ETF Q3 2026 Results: Net Income $1.48B, Up 418.4% YoY

Grayscale Bitcoin Mini Trust ETF reported a net increase in net assets from operations of $1.48 billion for the quarter ended September 30, 2026, primarily driven by $1.48 billion in unrealized appreciation of Bitcoin. As of September 30, 2026, the Trust held 63,087.34 Bitcoin with a fair value of $5.27 billion, representing a significant increase from the $4.24 billion held at year-end 2025.

Key figure
Net income $1.48B · +418.4% YoY
4:02 PM ET 10-Q
Financial Results Sarepta Therapeutics, Inc. SRPT

Sarepta Therapeutics Q3 2026 Results: Net Loss of $28.5M, Loss Narrows

Sarepta Therapeutics reported a net income of $297.6 million for the first nine months of 2026, a significant turnaround from a $301.2 million loss in the prior year period. Total revenues for the nine months reached $1.51 billion, driven by $983.0 million in net product sales and $530.4 million from collaboration and other revenue.

Key figure
Net loss $28.5M
4:02 PM ET 8-K
Financial Results Cardlytics, Inc. CDLX

Cardlytics Financial Results

Cardlytics reported third quarter 2026 financial results with revenue of $32.9 million, a 30% year-over-year decrease. Despite the revenue decline and a net loss of $8.9 million, the company achieved a positive Adjusted EBITDA of $0.4 million and highlighted progress in adding new partners and growing its advertising base.

“Our third quarter results came in below expectations. However, we remain encouraged by the progress towards our priorities. We are building supply by adding new CRP partners and continuing to grow our advertising base.”

Amit Gupta, CEO of Cardlytics

“We are running a leaner business, with lower costs, and a higher contribution margin. We expect sequential growth in the fourth quarter as we work toward self-sustainability.”

David Evans, CFO of Cardlytics
4:02 PM ET 10-Q
Financial Results Interactive Brokers Group, Inc. IBKR

Interactive Brokers Group Q3 2026 Results: Net Income $1.35B, Up 13.7% YoY

Interactive Brokers Group reported net revenues of $1,914 million for the quarter ended September 30, 2026, driven by strong growth in net interest income and commissions. Net income available for common stockholders rose to $314 million, while total assets increased to $243.2 billion compared to $203.2 billion at the end of 2025.

Key figure
Net income $1.35B · +13.7% YoY
4:02 PM ET 8-K
Loan & Debt Prospect Capital Corp PSEC

Prospect Capital $300M Debt Financing with U.S. Bank Trust Company, National Association

Prospect Capital Corporation issued $300 million in 8.95% senior unsecured notes due 2031. The notes were issued under a supplemental indenture with U.S. Bank Trust Company as trustee and closed on November 5, 2026. The company intends to use the $283.4 million in net proceeds primarily to refinance existing indebtedness.

Value
$300M
Counterparty
U.S. Bank Trust Company, National Association
Term
through Oct 2031
4:02 PM ET 8-K
Stock Buyback Arch Capital Group Ltd. ACGL

Arch Capital Group Announces $3B Stock Buyback

Arch Capital Group Ltd. increased its share repurchase authorization by $3.0 billion, bringing the total available capacity to approximately $3.6 billion. The company also declared quarterly dividends for its Series F and Series G non-cumulative preferred shares, payable on December 31, 2026.

Value
$3B
4:02 PM ET 10-Q
Financial Results Epam Systems, Inc. EPAM

Epam Systems Q3 2026 Results: Net Income $130M, Up 22.0% YoY

EPAM Systems reported revenues of $1.43 billion for the third quarter of 2026, a 2.3% increase compared to the same period in 2025. Net income for the nine months ended September 30, 2026, rose to $315.8 million from $268.3 million in the prior year, while the company significantly reduced its share count through $488.3 million in common stock repurchases during the first nine months of 2026.

Key figure
Net income $130M · +22.0% YoY
4:02 PM ET 10-Q
Financial Results Magnolia Oil & Gas Corp MGY ▶ Call

Magnolia Oil & Gas Q3 2026 Results: Net Income $80.5M, Up 6.7% YoY

Magnolia Oil & Gas reported a significant expansion in Q3 2026, driven by the $1.2 billion WildFire Acquisition and a public offering of common stock. Total assets grew from $2.9 billion to $7.4 billion year-to-date, while net income for the nine months ended September 30, 2026, rose to $363.1 million compared to $265.9 million in the prior year period.

Key figure
Net income $80.5M · +6.7% YoY
4:02 PM ET 8-K
Financial Results Omada Health, Inc. OMDA

Omada Health Financial Results

Omada Health reported Q3 2026 revenue of $91 million, a 34% year-over-year increase, and reached a record 1.1 million total members. The company achieved GAAP net income of $7 million compared to a loss in the prior year and raised its full-year 2026 revenue and Adjusted EBITDA guidance.

Term
Q3 2026

“Omada Health delivered its strongest quarter yet, with revenue growing 34% year over year, Total Members increasing 36% and a GAAP gross margin of 76%. Our diabetes and hypertension programs led that growth, and average tenure in our programs reached a record of roughly two years and four months. That gives members more time to build lasting habits and the confidence to manage their health.”

Sean Duffy, co-founder and CEO of Omada Health
4:02 PM ET 8-K
Leadership Change Longeveron Inc. LGVN

Longeveron Leadership Change

Ms. Ursula Ungaro resigned from Longeveron Inc.'s Board of Directors and all associated committees effective November 1, 2026. Her departure was due to personal health issues and was not the result of any disagreement with the company's operations, policies, or practices.

4:02 PM ET 8-K
Financial Results Celldex Therapeutics, Inc. CLDX

Celldex Therapeutics Financial Results

Celldex Therapeutics reported third quarter 2026 financial results and provided a corporate update on its barzolvolimab program. The company highlighted positive Phase 3 topline results in chronic spontaneous urticaria (CSU) and anticipates a BLA submission in 2027.

“Barzolvolimab has significant potential to address enormous populations of high unmet need and shift the treatment paradigm goal from symptom improvement to complete symptom resolution, which for patients means no itch, no hives, no swelling.”

Anthony Marucci, Co-founder, President and Chief Executive Officer

“This quarter we reported best-in-disease results from our two Phase 3 studies in CSU, demonstrating barzolvolimab’s unparalleled ability to deliver complete response to patients—including even in patient populations suffering with severe disease or severe angioedema or with omalizumab refractory disease.”

Anthony Marucci, Co-founder, President and Chief Executive Officer
4:02 PM ET 10-Q
Financial Results Ecovyst Inc. ECVT ▶ Call

Ecovyst Q3 2026 Results: Turns Profitable, Net Income $18.2M

Ecovyst Inc. reported a significant turnaround for the nine months ended September 30, 2026, with net income of $30.3 million compared to a net loss of $76.9 million in the prior year period. The improvement was driven by a 47.6% increase in sales to $773.6 million and the absence of the large $73.9 million loss from discontinued operations recorded in 2025.

Key figure
Net income $18.2M
4:02 PM ET 8-K
Divestiture BRC Group Holdings, Inc. RILY

BRC Group Holdings Divestiture to Oaktree Capital Management, L.P. for $62.2M

BRC Group Holdings completed the sale of its remaining membership interests in Great American Holdings, LLC to affiliates of Oaktree Capital Management for $62.25 million in cash. The company used approximately $51.7 million of the proceeds to repay outstanding term-loan indebtedness owed to Oaktree-affiliated lenders.

Value
$62.2M
Counterparty
Oaktree Capital Management, L.P.
4:01 PM ET 8-K
Business Update Acumen Pharmaceuticals, Inc. ABOS

Acumen Pharmaceuticals Business Update

Acumen Pharmaceuticals is implementing a major restructuring plan that includes reducing its workforce by approximately 90% (52 employees) following the decision to cease development of its lead candidate, sabirnetug. The company estimates it will incur $7.75 million in severance-related charges and has also fully repaid its $23.3 million outstanding debt to K2 HealthVentures to conserve cash while evaluating strategic options.

4:01 PM ET 10-Q
Financial Results Unity Bancorp Inc UNTY

Unity Bancorp Q3 2026 Results: Net Income $17.4M, Up 20.8% YoY

Unity Bancorp reported net income of $17.4 million for the third quarter of 2026, an increase from $14.4 million in the prior year period, driven by higher net interest income. Total assets grew to $3.25 billion as of September 30, 2026, primarily due to significant growth in the commercial loan portfolio.

Key figure
Net income $17.4M · +20.8% YoY
4:01 PM ET 8-K
Financial Results Perdoceo Education Corp PRDO

Perdoceo Education Financial Results

Perdoceo Education reported Q3 2026 financial results with revenue increasing 1.9% to $215.9 million and diluted EPS growing 16.7% to $0.70. The company noted strong student retention and interest, while confirming its acquisition of South University remains on track to close as early as April 2027.

Term
Q3 2026

“Third quarter operating performance was ahead of our expectations, as our portfolio of academic institutions experienced strong prospective student interest and student retention trended near historical highs.”

Todd Nelson, President and Chief Executive Officer

“Importantly, we remain committed to investing in student support and technology that we believe will further enhance both student experiences and academic outcomes. Looking ahead, we are on track to complete our acquisition of South University as early as April 2027, and expect to continue generating long-term, sustainable and responsible growth.”

Todd Nelson, President and Chief Executive Officer
4:01 PM ET 8-K
Financial Results Expensify, Inc. EXFY

Expensify Financial Results

Expensify reported Q3 2026 revenue of $33.0 million and a net loss of $3.3 million, while generating $3.3 million in free cash flow. The company highlighted explosive growth in its 'New Expensify' platform, where revenue increased 212% year-over-year, and raised its full-year 2026 free cash flow guidance.

Term
Q3 2026

“Expensify Classic is a stable cash-flow engine whose customer base naturally declines over time, while New Expensify is our growth engine. That growth engine is taking on a massive, largely untapped market.”

David Barrett, Founder and CEO of Expensify
4:01 PM ET 8-K
Financial Results Unusual Machines, Inc. UMAC

Unusual Machines Financial Results

Unusual Machines reported Q3 2026 revenue of $13.9 million, a 551% increase year-over-year, driven by expansion in U.S. manufacturing and the acquisition of Upgrade Energy. Despite a GAAP net loss of $25 million primarily due to non-cash investment losses, the company maintained gross margins of 35.4% and reported a narrow adjusted EBITDA loss of $0.7 million.

Term
Q3 2026

“I am extremely encouraged by our relatively small adjusted EBITDA loss in a quarter where revenue does not yet reflect the benefits of our ongoing investments in growth. I continue to believe that Unusual Machines can achieve positive adjusted EBITDA in 2027 without compromising our growth plans.”

Allan Evans, CEO
4:01 PM ET 10-Q
Financial Results Heritage Global Inc. HGBL

Heritage Global Q3 2026 Results: Net Income $1.04M, Up 77.3% YoY

Heritage Global Inc. reported a net loss of $14.1 million for the nine months ended September 30, 2026, primarily driven by a $17.7 million loss from equity method investments. Despite the year-to-date loss, the company achieved a net income of $1.0 million in the third quarter of 2026, supported by growth in both services revenue and asset sales.

Key figure
Net income $1.04M · +77.3% YoY
4:01 PM ET 10-Q
Financial Results Inmune Bio, Inc. INMB

Inmune Bio Q3 2026 Results: Net Loss of $4.72M, Loss Narrows

For the nine months ended September 30, 2026, INmune Bio reported a net loss of $11.4 million, a significant reduction from the $40.7 million loss in the prior year period which included a $16.5 million impairment charge. The company reported zero revenue for the 2026 period and expressed substantial doubt about its ability to continue as a going concern due to insufficient liquidity to sustain operations for the next twelve months.

Key figure
Net loss $4.72M
4:01 PM ET 10-Q
Financial Results Onterris, Inc. ONT

Onterris Q3 2026 Results: Net Income $8.99M, Up 7.3% YoY

Onterris, Inc. reported a net income of $9.0 million for the third quarter of 2026, though it sustained a net loss of $2.3 million for the nine months ended September 30, 2026. Revenues declined year-over-year for both the three and nine-month periods, while the company actively repurchased approximately $30 million of its common stock during the first nine months of the year.

Key figure
Net income $8.99M · +7.3% YoY
4:01 PM ET 8-K
Financial Results Carlyle Secured Lending, Inc. CGBD

Carlyle Secured Lending Financial Results

Carlyle Secured Lending, Inc. reported Q3 2026 financial results with Net Investment Income of $0.36 per share and a 0.3% increase in NAV per share to $15.65. The company also declared a Q4 2026 dividend of $0.35 per share payable in January 2027.

Term
Q3 2026

“We continued to execute CGBD’s strategy in the third quarter, resulting in increased earnings and a stable NAV. Given the uncertain market backdrop, we were selective in deploying new capital and continue to leverage the OneCarlyle platform to capture differentiated opportunities across the private credit market. Looking ahead to the end of the year, we remain focused on delivering disciplined credit performance and continuing to scale our joint ventures.”

Alex Chi, CGBD’s Chief Executive Officer
4:01 PM ET 10-Q
Financial Results Nephros Inc NEPH

Nephros Q3 2026 Results: Net Income $512K, Up 51.9% YoY

Nephros, Inc. reported a 20% increase in total net revenues to $16.9 million for the nine months ended September 30, 2026, compared to $14.1 million in the prior year period. The company achieved a net income of $1.85 million for the first nine months of 2026, up from $1.13 million in 2025, driven by growth in product revenues and improved operating income.

Key figure
Net income $512K · +51.9% YoY
4:01 PM ET 10-Q
Financial Results AGNT, Inc. AGNT

AGNT Q3 2026 Results: Net Loss of $4.26M

AGNT, Inc. reported a net loss of $4.3 million for the third quarter of 2026, compared to a net income of $3.5 million in the prior year period, despite a 5.8% increase in quarterly revenue to $1.39 billion. The loss was primarily driven by higher commissions and agent-related costs, as well as a significant $6.5 million loss from unconsolidated affiliates. For the nine months ended September 30, 2026, the company recorded a net loss of $12.0 million.

Key figure
Net loss $4.26M
4:01 PM ET 10-Q
Financial Results National Healthcare Corp NHC

National Healthcare Q3 2026 Results: Net Income $13.6M, Down 65.2% YoY

National HealthCare Corp reported its financial results for the third quarter of 2026, highlighting consistent revenue performance across its skilled nursing and assisted living facilities. The filing indicates a focus on managing rising labor costs while maintaining stable occupancy levels, though specific future guidance was not detailed in the primary financial statements.

Key figure
Net income $13.6M · -65.2% YoY
4:01 PM ET 8-K
Clinical Trial Data Pmgc Holdings Inc. ELAB

Pmgc Holdings Clinical Trial Data

PMGC Holdings announced results from a preclinical study of its engineered probiotic candidate EL-32, both as a standalone and in combination with semaglutide. The study identified a statistically significant greater absolute lean mass at the highest EL-32 dose compared to semaglutide alone, supporting the company's muscle-preservation thesis. While the combination improved insulin sensitivity and reduced body weight, it did not demonstrate a consistent additive metabolic benefit over semaglutide alone across all measures.

4:01 PM ET 8-K
Financial Results Consensus Cloud Solutions, Inc. CCSI

Consensus Cloud Solutions Financial Results

Consensus Cloud Solutions reported Q3 2026 revenue of $91.0 million, a 3.7% increase year-over-year, driven by 9.1% growth in its Corporate business. The company narrowed its full-year 2026 revenue and Adjusted EBITDA guidance while raising its Adjusted EPS outlook. During the quarter, the company repurchased approximately 550,000 shares and amended its credit facility to prepare for retiring debt in 2027.

Term
Q3 2026

“Our Q3 achievements continued the momentum of the past few quarters. Our corporate channel exceeded 9% revenue growth for the second straight quarter. We also experienced sustained improvement in the SoHo channel within the range of our expectations. In addition, we were able to repurchase approximately 550,000 shares of our common stock during the quarter at what we believe are attractive prices. Finally, we amended our credit facility in anticipation of retiring the 6.5% Notes in 2027.”

Scott Turicchi, CEO of Consensus
4:00 PM ET 8-K
Leadership Change Renatus Tactical Acquisition Corp I RTAC

Renatus Tactical Acquisition Corp I Leadership Change

Devin G. Nunes resigned as a director and Chairman of the Board of Renatus Tactical Acquisition Corp I, effective October 31, 2026. The company stated the resignation was not due to any dispute or disagreement and is currently searching for an independent director to fill the vacancy.

3:59 PM ET 8-K
Financial Results AGNT, Inc. AGNT

AGNT Financial Results

AGNT, Inc. reported Q3 2026 financial results with revenue increasing 6% year-over-year to $1.4 billion, though the company swung to a net loss of $4.3 million. The company also declared a quarterly cash dividend of $0.05 per share and provided Q4 revenue guidance of $1.0 billion to $1.2 billion.

“AGNT’s third-quarter results reflect a business with more agents, and more productive agents, than a year ago, and a financial position that we believe leaves us well-positioned to lead the industry through challenging times.”

Leo Pareja, CEO of AGNT, Inc.

“Our third quarter reflects the strength of the financial model we've built and the discipline of the team that runs it. We grew the top line in a housing market that remains challenging, and we’re delivering on our goal to manage the business with discipline while continuing to invest in innovation for our agents.”

Jesse Hill, CFO of AGNT, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.